Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure

Next Previous
Trial Profile

A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin
  • Indications Thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
  • Acronyms UNIVERSE
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 20 Dec 2021 According to a Janssen Pharmaceuticals media release, based on the EINSTEIN-Jr and UNIVERSE studies, the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO: the treatment of venous thromboembolism and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after initial parenteral anticoagulant treatment; and thromboprophylaxis in children aged 2 years and older with congenital heart disease who have undergone Fontan procecedure
    • 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183942).
    • 27 Sep 2021 Results presented in a Bayer Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top